Blue Owl reports 0.76% warrant stake in enGene

enGene Therapeutics Inc. received an updated Schedule 13G/A from Blue Owl Capital Holdings LP reporting a small, warrant-based position in its common shares.

Rhea-AI Filing Summary

enGene Therapeutics Inc. received an updated Schedule 13G/A from Blue Owl Capital Holdings LP reporting a small, warrant-based position in its common shares. Blue Owl reports sole voting and dispositive power over 511,177 Common Shares, all issuable upon exercise of warrants, each to acquire one Common Share.

This position represents 0.76% of enGene’s Common Shares, calculated using 66,989,466 Common Shares outstanding as of June 9, 2026 and adding the shares underlying the warrants. Blue Owl characterizes its holdings as ownership of 5 percent or less of the class and, under Rule 13d-4, states that this filing should not be deemed an admission that it is the beneficial owner of the reported securities for purposes of Sections 13(d) or 13(g) or for any other purpose.

Key Figures

Shares underlying warrants: 511,177 Common Shares Ownership percentage: 0.76% Shares outstanding: 66,989,466 Common Shares +2 more

5 metrics

Shares underlying warrants 511,177 Common Shares Common Shares issuable upon exercise of warrants held by Blue Owl Capital Holdings

Ownership percentage 0.76% Percent of enGene Common Shares represented by the warrant position

Shares outstanding 66,989,466 Common Shares Common Shares outstanding as of June 9, 2026, used for percentage calculation

Sole voting power 511,177 shares Shares over which Blue Owl Capital Holdings reports sole voting power

Shared voting power 0 shares Shares over which Blue Owl Capital Holdings reports shared voting power

Key Terms

beneficial owner, Rule 13d-4, Sole Voting Power, Sole Dispositive Power, +1 more

5 terms

beneficial owner regulatory

"shall not be deemed an admission that the Reporting Person is a beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Rule 13d-4 regulatory

"Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that"

Sole Voting Power regulatory

"5 | Sole Voting Power 511,177.00 6 | Shared Voting Power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power regulatory

"7 | Sole Dispositive Power 511,177.00 8 | Shared Dispositive Power"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Ownership of 5 percent or less of a class regulatory

"Item 5. | Ownership of 5 Percent or Less of a Class."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in ENGN does Blue Owl Capital Holdings report in this Schedule 13G/A?

Blue Owl Capital Holdings reports an indirect position equal to 0.76% of enGene’s Common Shares, based on 511,177 shares issuable upon exercise of warrants and an outstanding share count of 66,989,466.

How many ENGN shares are linked to Blue Owl Capital Holdings’ warrants?

Blue Owl Capital Holdings reports warrants exercisable into 511,177 Common Shares of enGene Therapeutics Inc., with each warrant exercisable to acquire one Common Share upon exercise.

Does Blue Owl Capital Holdings control voting power over its ENGN-related securities?

Blue Owl Capital Holdings reports sole voting power over 511,177 shares and no shared voting power, reflecting control tied to warrants exercisable into enGene Common Shares.

Is Blue Owl Capital Holdings a major (over 5%) holder of ENGN stock?

No. Blue Owl Capital Holdings’ reported position equals 0.76% of enGene’s Common Shares, and the filing classifies this as ownership of 5 percent or less of the class.

What disclaimer does Blue Owl Capital Holdings include about ENGN beneficial ownership?

Blue Owl invokes Rule 13d-4, stating that submitting this Schedule 13G/A shall not be deemed an admission that it is the beneficial owner of the reported securities for Section 13(d) or 13(g) purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 04:31 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

enGene Therapeutics Inc.

(Name of Issuer)

Common Shares, no par value

(Title of Class of Securities)

29286X101

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29286X101

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 511,177.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 511,177.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

511,177.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.76 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported securities represent 511,177 Common Shares issuable upon exercise of warrants to each acquire one Common Share ("Warrants"). The reported percentage is calculated based on 66,989,466 Common Shares outstanding as of June 9, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on June 15, 2026, and as increased by the 511,177 Common Shares issuable upon exercise of the Warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: enGene Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada, H4R 2P1
Item 2.
(a)	Name of person filing: This Statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue, New York, New York 10022
(c)	Citizenship: See response to row 4 on the cover page hereto.
(d)	Title of class of securities: Common Shares, no par value
(e)	CUSIP No.: 29286X101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to row 9 on the cover page hereto. Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this Statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.
(b)	Percent of class: See response to row 11 on the cover page hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to row 5 on the cover page hereto.
	(ii) Shared power to vote or to direct the vote: See response to row 6 on the cover page hereto.
	(iii) Sole power to dispose or to direct the disposition of: See response to row 7 on the cover page hereto.
	(iv) Shared power to dispose or to direct the disposition of: See response to row 8 on the cover page hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager / Chief Compliance Officer
Date:	08/12/2026